Gastops Validates ChipCHECK® Debris Analysis Technology for Pratt & Whitney F135 Engine / Lockheed Martin F-35 Lightning II
OTTAWA, ON, May 28, 2026 /PRNewswire/ -- Gastops Ltd., a global leader in intelligent condition monitoring solutions for aerospace and defence applications, today announced the successful validation of its next generation debris analysis technology,...
ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation...
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven...
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for...
Gastops Receives Investment from RTX for Next Generation Monitoring Technologies
Investment made possible by Canadian Industrial and Technological Benefits Policy (ITB) OTTAWA, ON, May 29, 2025 /PRNewswire/ -- Gastops Ltd. is announcing a joint agreement under Canada's Industrial and Technology Benefits (ITB) policy for a...